foscarnet has been researched along with Acquired Immune Deficiency Syndrome in 221 studies
Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.
phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A cohort of 24 patients with acquired immunodeficiency syndrome (AIDS) and CMV retinitis received sodium phosphonoformate (foscarnet) as part of a controlled efficacy trial at the National Institutes of Health." | 10.17 | Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). ( Baird, BF; Davey, RT; deSmet, MD; Falloon, J; Kovacs, JA; Masur, H; Mellow, S; Nussenblatt, RB; Palestine, AG; Polis, MA, 1993) |
| "The Cytomegalovirus Retinitis Retreatment Trial was a multicenter clinical trial designed to evaluate three treatments for the treatment of relapsed CMV retinitis; (1) foscarnet; (2) 'high-dose' ganciclovir, and (3) combination foscarnet and ganciclovir." | 9.08 | Design of clinical trials for drug combinations: cytomegalovirus retinitis--foscarnet and ganciclovir. The CMV retinitis retreatment trial. ( Jabs, DA, 1996) |
| "Four intravenous dosages of foscarnet given for 10 days were compared with no therapy in persons with AIDS who had asymptomatic cytomegalovirus (CMV) viremia." | 9.08 | Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. ( Acosta, EP; Balfour, HH; Boivin, G; Crumpacker, CS; Eaton, CA; Erice, A; Fletcher, CV; Henry, WK; Holm, MA; Martin-Munley, SS; Shepp, DH; Smith, SA, 1996) |
| "Eleven clinical centers, a data coordinating center, and a fundus photograph reading center participated in a randomized, controlled, multicenter clinical trial comparing foscarnet and ganciclovir as primary therapy for previously untreated CMV retinitis in 240 patients with AIDS." | 9.08 | Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. ( , 1997) |
| "The safety and efficacy of cidofovir gel for treatment of acyclovir-unresponsive herpes simplex virus infections in AIDS patients was evaluated in a randomized, double-blind, multicenter trial." | 9.08 | A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. ( Boggs, J; Cheung, T; Corey, L; Drew, WL; Feinberg, J; Gathe, J; Jaffe, HS; Kessler, H; Kramer, F; Lalezari, J; Lee, S; McGuire, B; Safrin, S; Schacker, T, 1997) |
| "The pharmacodynamic relationship between a range of foscarnet exposure measurements obtained from studying nine patients receiving ongoing maintenance therapy for cytomegalovirus retinitis and a range of efficacy values (days to retinitis progression) obtained by independent examination of serial retinal photographs from the same nine patients was analyzed." | 9.07 | Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis. ( Causey, D; Davis, R; Feinberg, J; Heinemann, MH; Jacobson, MA; Kuppermann, BD; Lizak, P; O'Donnell, JJ; Polsky, B; Tong, W, 1994) |
| "In a controlled trial of foscarnet in the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS), patients with non-immediately sight-threatening lesions were randomized to receive immediate treatment with foscarnet or foscarnet treatment delayed until the first signs of retinitis progression." | 9.07 | Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome. ( Polis, MA, 1992) |
| "Circulating human immunodeficiency virus (HIV) p24 antigen levels were measured in 22 AIDS patients who had detectable serum antigen at baseline after induction and maintenance therapy of foscarnet for cytomegalovirus retinitis in phase I/II multicenter trials." | 9.07 | Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. ( Causey, DM; Davis, RB; Grieco, MH; Hooton, TM; Jacobson, MA; McKinley, GF; Parenti, DM; Reddy, MM; van der Horst, CM, 1992) |
| "Ganciclovir and Foscarnet were compared in an open randomised trial as treatment and secondary prophylaxis of cytomegalovirus (CMV) retinitis in patients with AIDS." | 9.07 | Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison. ( Gazzard, BG; Harman, C; Mathalone, B; Mitchell, S; Moyle, G, 1992) |
| "We performed a multicenter, randomized, unblinded clinical trial (the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial) designed to compare ganciclovir with foscarnet in the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS)." | 9.07 | Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. ( , 1992) |
| "Herpes simplex virus (HSV) resistant to acyclovir can produce persistent mucocutaneous ulcerative disease in patients with the acquired immunodeficiency syndrome (AIDS)." | 9.07 | Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. ( Hardy, WD, 1992) |
| "To evaluate foscarnet sodium in treating cytomegalovirus retinitis in patients with AIDS." | 9.07 | A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. ( Baird, BF; Davey, RT; Davis, M; De Smet, MD; Falloon, J; Kovacs, JA; Palestine, AG; Polis, MA; Zunich, KM; Zurlo, JJ, 1991) |
| "Persons with AIDS who have CD4+ counts < or = 100 and transplant patients, especially bone marrow allograft recipients, may experience clinically significant infections with acyclovir-resistant herpes simplex virus (HSV) or varicella-zoster virus (VZV)." | 8.79 | Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. ( Balfour, HH; Benson, C; Braun, J; Cassens, B; Erice, A; Friedman-Kien, A; Klein, T; Polsky, B; Safrin, S, 1994) |
| "The pyrophosphate analogue, foscarnet, selectively inhibits the DNA polymerase of human herpes viruses, including cytomegalovirus, and the reverse transcriptase of HIV." | 8.78 | Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. ( Chrisp, P; Clissold, SP, 1991) |
| "Sequential human-immunodeficiency virus type 1 (HIV-1) isolates from an acquired immunodeficiency syndrome (AIDS) patient on long-term foscarnet and zidovudine therapy were examined for the emergence of foscarnet resistance." | 7.69 | Long-term foscarnet therapy not associated with the development of foscarnet-resistant human immunodeficiency virus type 1 in an acquired immunodeficiency syndrome patient. ( Birch, C; Hoy, J; McGavin, K; Tachedjian, G, 1994) |
| "This study evaluated intravitreous and plasma ganciclovir and foscarnet concentrations after intravenous administration in AIDS patients with cytomegalovirus (CMV) retinitis and retinal detachment." | 7.69 | Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. ( Arevalo, JF; Bergeron-Lynn, G; Capparelli, EV; Connor, JD; Freeman, WR; Gambertoglio, J; Garcia, RF; Gonzalez, C; Kirsch, LS; Quiceno, JI, 1995) |
| "Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring greater than 6 mumols of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy." | 7.68 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. ( Drew, WL; Feinberg, J; Jacobson, MA; Miner, RD; O'Donnell, JJ; Parenti, D; Whitmore, PV, 1991) |
| "Foscarnet, administered via a central line, was used for the treatment of 18 episodes of cytomegalovirus (CMV) esophageal ulceration in 15 patients, and in the treatment of 27 episodes of CMV colitis in 22 patients." | 7.68 | Foscarnet in the treatment of cytomegalovirus infection of the esophagus and colon in patients with the acquired immune deficiency syndrome. ( Connolly, GM; Gazzard, BG; Hawkins, DA; Nelson, MR, 1991) |
| "Foscarnet is an investigational antiviral agent that has been used effectively in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients." | 7.68 | Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. ( Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991) |
| "Mucocutaneous herpes simplex virus (HSV) infections that are resistant to therapy with acyclovir have been recognized with increasing frequency in patients with the acquired immunodeficiency syndrome, although alternative therapies in this setting have not been widely studied." | 7.68 | Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. ( Assaykeen, T; Follansbee, S; Mills, J; Safrin, S, 1990) |
| "The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3'-azido-3'-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4+ HeLa cells." | 7.67 | HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. ( Darby, G; Larder, BA; Richman, DD, 1989) |
| "To determine whether trisodium phosphonoformate (foscarnet) is efficacious in treating severe mucocutaneous disease due to acyclovir-resistant herpes simplex virus type-2 (HSV-2) infection in patients with the acquired immunodeficiency syndrome (AIDS)." | 7.67 | Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. ( Drennan, DP; Erlich, KS; Follansbee, SE; Gooze, L; Jacobson, MA; Koehler, JE; Mills, J; Safrin, S, 1989) |
| "Ten patients with acquired immunodeficiency syndrome with newly diagnosed cytomegalovirus (CMV) retinitis were treated with an induction regimen of intravenous foscarnet, 60 mg/kg of body weight, administered as a 2-h infusion and repeated every 8 h for 14 days." | 7.67 | Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. ( Jacobson, MA; Mills, J; O'Donnell, JJ, 1989) |
| " There was no difference between the 2 groups in either serious adverse events or rise of creatinine to > or = 2." | 6.69 | Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections. ( Benson, P; Cheung, TW; Jayaweera, DT; Nahass, R; Olson, C; Pearce, D; Wool, GM, 2000) |
| "Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42." | 6.67 | A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. ( Chatis, P; Crumpacker, C; Davis, R; Hafner, R; Kessler, HA; Landry, B; Mills, J; Rush, J; Safrin, S, 1991) |
| "Treatment with Foscarnet may be initially effective, but does not eliminate cytomegalovirus infection." | 6.66 | Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with Foscarnet (phosphonoformate). ( Barrison, I; Boylston, A; Forster, S; Jeffries, DJ; Pinching, AJ; Thom, S; Unwin, R; Weber, JN, 1987) |
| "A cohort of 24 patients with acquired immunodeficiency syndrome (AIDS) and CMV retinitis received sodium phosphonoformate (foscarnet) as part of a controlled efficacy trial at the National Institutes of Health." | 6.17 | Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet). ( Baird, BF; Davey, RT; deSmet, MD; Falloon, J; Kovacs, JA; Masur, H; Mellow, S; Nussenblatt, RB; Palestine, AG; Polis, MA, 1993) |
| "The lymphoproliferative disorders are usually treated with a combination of cytotoxic drugs, and virustatic medication is thought to be ineffective." | 5.31 | Regression of Epstein-Barr virus-associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet. ( Delecluse, HJ; Huhn, D; Ruhnke, M; Schneider, U; Stein, H, 2000) |
| "A 41-year-old man with acquired immunodeficiency syndrome (AIDS) developed cytomegalovirus (CMV) retinitis." | 5.29 | [Foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome]. ( Fujino, Y; Kimura, S; Mochizuki, M; Mouri, H; Nagata, Y; Oka, S; Ono, A; Shimada, K, 1994) |
| "Virus isolates from four AIDS patients and one bone marrow transplant recipient were examined for their sensitivity for the antiviral compounds used by means of plaque reduction assay." | 5.28 | [Acyclovir-resistant herpes simplex virus infections in immunocompromised patients]. ( Frissen, PH; Jansen, CL; Maris-Tegeler, WG; van der Noordaa, J; Weiland, HT; Wertheim-van Dillen, PM, 1992) |
| "Foscarnet was discontinued because of adverse events in 3 (3%) of 97 patients, with treatment being stopped in 2 patients because of renal insufficiency and in 1 patient because of an acute neurologic disorder." | 5.28 | Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens. ( Brancon, C; Caumes, E; Cochereau-Massin, I; Dahan, R; Dohin, E; Gentilini, M; Katlama, C; Robinet, M; Rogeaux, O, 1992) |
| "We treated a patient who had acquired immunodeficiency syndrome and cytomegalovirus retinitis of the left eye." | 5.28 | Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. ( Chipont, E; Díaz-Llopis, M; España, E; Menezo, JL; Navea, A; Sanchez, S, 1992) |
| "Foscarnet has been shown to be active in vitro against the human immunodeficiency virus and all human herpesviruses including cytomegalovirus (CMV)." | 5.28 | Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. ( Aweeka, F; Gambertoglio, J; Jacobson, MA; Mills, J, 1989) |
| "Foscarnet inhibits human immunodeficiency virus (HIV) replication in vitro and decreases p24 antigenemia in patients with cytomegalovirus (CMV) retinitis." | 5.08 | Foscarnet decreases human immunodeficiency virus RNA. ( Furrer, H; Hirschel, B; Kaiser, L; Olmari, M; Perrin, L; Von Overbeck, J; Yerly, S, 1995) |
| "The Cytomegalovirus Retinitis Retreatment Trial was a multicenter clinical trial designed to evaluate three treatments for the treatment of relapsed CMV retinitis; (1) foscarnet; (2) 'high-dose' ganciclovir, and (3) combination foscarnet and ganciclovir." | 5.08 | Design of clinical trials for drug combinations: cytomegalovirus retinitis--foscarnet and ganciclovir. The CMV retinitis retreatment trial. ( Jabs, DA, 1996) |
| "Four intravenous dosages of foscarnet given for 10 days were compared with no therapy in persons with AIDS who had asymptomatic cytomegalovirus (CMV) viremia." | 5.08 | Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS. ( Acosta, EP; Balfour, HH; Boivin, G; Crumpacker, CS; Eaton, CA; Erice, A; Fletcher, CV; Henry, WK; Holm, MA; Martin-Munley, SS; Shepp, DH; Smith, SA, 1996) |
| "Eleven clinical centers, a data coordinating center, and a fundus photograph reading center participated in a randomized, controlled, multicenter clinical trial comparing foscarnet and ganciclovir as primary therapy for previously untreated CMV retinitis in 240 patients with AIDS." | 5.08 | Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. ( , 1997) |
| "The safety and efficacy of cidofovir gel for treatment of acyclovir-unresponsive herpes simplex virus infections in AIDS patients was evaluated in a randomized, double-blind, multicenter trial." | 5.08 | A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS. ( Boggs, J; Cheung, T; Corey, L; Drew, WL; Feinberg, J; Gathe, J; Jaffe, HS; Kessler, H; Kramer, F; Lalezari, J; Lee, S; McGuire, B; Safrin, S; Schacker, T, 1997) |
| "The pharmacodynamic relationship between a range of foscarnet exposure measurements obtained from studying nine patients receiving ongoing maintenance therapy for cytomegalovirus retinitis and a range of efficacy values (days to retinitis progression) obtained by independent examination of serial retinal photographs from the same nine patients was analyzed." | 5.07 | Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis. ( Causey, D; Davis, R; Feinberg, J; Heinemann, MH; Jacobson, MA; Kuppermann, BD; Lizak, P; O'Donnell, JJ; Polsky, B; Tong, W, 1994) |
| "Foscarnet was discontinued due to progressive renal insufficiency in all three patients (days 11, 19, and 21)." | 5.07 | A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet. ( Koenig, S; Polis, MA; Seidel, EA, 1993) |
| "In a controlled trial of foscarnet in the treatment of cytomegalovirus (CMV) retinitis in patients with the acquired immunodeficiency syndrome (AIDS), patients with non-immediately sight-threatening lesions were randomized to receive immediate treatment with foscarnet or foscarnet treatment delayed until the first signs of retinitis progression." | 5.07 | Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome. ( Polis, MA, 1992) |
| "Circulating human immunodeficiency virus (HIV) p24 antigen levels were measured in 22 AIDS patients who had detectable serum antigen at baseline after induction and maintenance therapy of foscarnet for cytomegalovirus retinitis in phase I/II multicenter trials." | 5.07 | Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis. ( Causey, DM; Davis, RB; Grieco, MH; Hooton, TM; Jacobson, MA; McKinley, GF; Parenti, DM; Reddy, MM; van der Horst, CM, 1992) |
| "Ganciclovir and Foscarnet were compared in an open randomised trial as treatment and secondary prophylaxis of cytomegalovirus (CMV) retinitis in patients with AIDS." | 5.07 | Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison. ( Gazzard, BG; Harman, C; Mathalone, B; Mitchell, S; Moyle, G, 1992) |
| "We performed a multicenter, randomized, unblinded clinical trial (the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial) designed to compare ganciclovir with foscarnet in the treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome (AIDS)." | 5.07 | Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. ( , 1992) |
| "Herpes simplex virus (HSV) resistant to acyclovir can produce persistent mucocutaneous ulcerative disease in patients with the acquired immunodeficiency syndrome (AIDS)." | 5.07 | Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial. ( Hardy, WD, 1992) |
| "To evaluate foscarnet sodium in treating cytomegalovirus retinitis in patients with AIDS." | 5.07 | A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS. ( Baird, BF; Davey, RT; Davis, M; De Smet, MD; Falloon, J; Kovacs, JA; Palestine, AG; Polis, MA; Zunich, KM; Zurlo, JJ, 1991) |
| "Foscarnet was administered by continuous intravenous infusion in 15 patients with the acquired immunodeficiency syndrome (AIDS) in an open, uncontrolled study." | 5.06 | The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients. ( Faber, V; Gaub, J; Gerstoft, J; Hofmann, B; Lernestedt, JO; Lindhardt, BO; Mathiesen, LR; Pedersen, C; Poulsen, AG; Ulrich, K, 1987) |
| "Persons with AIDS who have CD4+ counts < or = 100 and transplant patients, especially bone marrow allograft recipients, may experience clinically significant infections with acyclovir-resistant herpes simplex virus (HSV) or varicella-zoster virus (VZV)." | 4.79 | Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections. ( Balfour, HH; Benson, C; Braun, J; Cassens, B; Erice, A; Friedman-Kien, A; Klein, T; Polsky, B; Safrin, S, 1994) |
| "The nucleoside analog acyclovir is remarkably effective and selective in herpes simplex virus (HSF) infections." | 4.78 | [Resistance of herpes simplex viruses to antiviral drugs]. ( Bianchi, A; Scieux, C, 1993) |
| " The antiviral agents ganciclovir and foscarnet are effective against CMV retinitis and gastrointestinal diseases, although dose-limiting adverse effects and the need for long-term maintenance therapy may hinder their use in many patients." | 4.78 | Treatment and prophylaxis of cytomegalovirus disease. ( Jacobson, PA; Levinson, ML, 1992) |
| "The pyrophosphate analogue, foscarnet, selectively inhibits the DNA polymerase of human herpes viruses, including cytomegalovirus, and the reverse transcriptase of HIV." | 4.78 | Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis. ( Chrisp, P; Clissold, SP, 1991) |
| "Seventeen AIDS patients with cytomegalovirus (CMV), herpes simplex virus (HSV), varicella-zoster virus (VZV) infection, Kaposi's sarcoma (KS), or a combination of these were treated with foscarnet." | 3.70 | Foscarnet decreases HIV-1 plasma load. ( Barbeau, P; Breilh, D; Denisi, R; Devianne-Garrigue, I; Dupon, M; Fleury, HJ; Leng, B; Pellegrin, I; Pellegrin, JL; Ragnaud, JM, 1998) |
| "Three acquired immune deficiency syndrome patients given foscarnet to treat cytomegalovirus retinitis developed renal failure with crystal deposits within the renal glomeruli." | 3.70 | Identification of crystals in kidneys of AIDS patients treated with foscarnet. ( Beaufils, H; Daudon, M; Jouanneau, C; Katlama, C; Lacour, B; Maurice-Estepa, L; Sazdovitch, V, 1998) |
| "A patient with AIDS and cytomegalovirus (CMV) retinitis received ganciclovir and foscarnet for 20 and 5 months, respectively, with evidence of periodic disease progression." | 3.70 | A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance. ( Chou, S; Drew, WL; Miner, RC, 2000) |
| "Sequential human-immunodeficiency virus type 1 (HIV-1) isolates from an acquired immunodeficiency syndrome (AIDS) patient on long-term foscarnet and zidovudine therapy were examined for the emergence of foscarnet resistance." | 3.69 | Long-term foscarnet therapy not associated with the development of foscarnet-resistant human immunodeficiency virus type 1 in an acquired immunodeficiency syndrome patient. ( Birch, C; Hoy, J; McGavin, K; Tachedjian, G, 1994) |
| "This study evaluated intravitreous and plasma ganciclovir and foscarnet concentrations after intravenous administration in AIDS patients with cytomegalovirus (CMV) retinitis and retinal detachment." | 3.69 | Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis. ( Arevalo, JF; Bergeron-Lynn, G; Capparelli, EV; Connor, JD; Freeman, WR; Gambertoglio, J; Garcia, RF; Gonzalez, C; Kirsch, LS; Quiceno, JI, 1995) |
| "We report two cases of seizures and one case of hand cramping and finger paresthesia after starting foscarnet therapy with no evidence of predisposing risk factors, such as serum laboratory abnormalities, renal dysfunction, or known central nervous system (CNS) involvement." | 3.69 | Neurologic sequelae associated with foscarnet therapy. ( Liu, YQ; Lor, E, 1994) |
| "Advances in ganciclovir and foscarnet therapies for treating cytomegalovirus retinitis, including ocular implants and injections, alternating use of foscarnet and ganciclovir, oral ganciclovir use, cidofovir treatment, and injecting either ganciclovir or foscarnet directly into affected eyes, are discussed." | 3.69 | Advances in treatment for cytomegalovirus retinitis. ( Bowers, M, 1995) |
| "Cytomegalovirus (CMV) retinitis, a sight-threatening infection common in AIDS patients, can be treated systemically with intravenous ganciclovir, intravenous foscarnet, or oral ganciclovir." | 3.69 | Intraocular therapy for cytomegalovirus retinitis. ( Palestine, AG, 1996) |
| "Foscarnet and ganciclovir appear to be of similar effectiveness in halting active infection when given as induction therapy and in forestalling progression of disease when given as maintenance therapy in persons with AIDS who have cytomegalovirus (CMV) retinitis." | 3.68 | Therapeutic algorithm for treatment of cytomegalovirus retinitis in persons with AIDS. A roundtable summary. ( Balfour, HH; Drew, WL; Hardy, WD; Heinemann, MH; Polsky, B, 1992) |
| "Three AIDS patients with severe cutaneous herpes simplex virus (HSV) infection refractory to therapy with acyclovir and foscarnet (2 patients) were treated with a topical preparation of trifluorothymidine (TFT) and interferon-alpha." | 3.68 | Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections. ( Birch, CJ; Doherty, R; Hayes, K; Lucas, CR; Mijch, A; Tachedjian, G; Tyssen, DP, 1992) |
| "Infections caused by cytomegalovirus (CMV) resistant in vitro to ganciclovir, defined as requiring greater than 6 mumols of ganciclovir for ED50 have developed in some AIDS patients with progressive CMV retinitis despite chronic ganciclovir therapy." | 3.68 | Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS. ( Drew, WL; Feinberg, J; Jacobson, MA; Miner, RD; O'Donnell, JJ; Parenti, D; Whitmore, PV, 1991) |
| "To determine whether foscarnet has potential efficacy in the treatment of acyclovir-resistant mucocutaneous varicella-zoster infection in patients with the acquired immunodeficiency syndrome (AIDS)." | 3.68 | Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection. ( Berger, TG; Biron, KK; Gilson, I; Mills, J; Safrin, S; Wofsy, CB; Wolfe, PR, 1991) |
| "Foscarnet, administered via a central line, was used for the treatment of 18 episodes of cytomegalovirus (CMV) esophageal ulceration in 15 patients, and in the treatment of 27 episodes of CMV colitis in 22 patients." | 3.68 | Foscarnet in the treatment of cytomegalovirus infection of the esophagus and colon in patients with the acquired immune deficiency syndrome. ( Connolly, GM; Gazzard, BG; Hawkins, DA; Nelson, MR, 1991) |
| "Foscarnet is an investigational antiviral agent that has been used effectively in the treatment of cytomegalovirus (CMV) retinitis in AIDS patients." | 3.68 | Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. ( Gambertoglio, JG; Graziani, AL; Grunwald, JE; MacGregor, RR; Weiss, R, 1991) |
| "In an AIDS patient who had repeated successful treatment with acyclovir in his history, erosive herpes perianalis with herpes proctitis appeared, which persisted over several weeks." | 3.68 | [Chronic erosive, therapy-resistant perianal herpes (type II) with herpes proctitis in AIDS]. ( Bratzke, B; Ehlers, G; Orfanos, CE; Stavermann, T, 1991) |
| "Mucocutaneous herpes simplex virus (HSV) infections that are resistant to therapy with acyclovir have been recognized with increasing frequency in patients with the acquired immunodeficiency syndrome, although alternative therapies in this setting have not been widely studied." | 3.68 | Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data. ( Assaykeen, T; Follansbee, S; Mills, J; Safrin, S, 1990) |
| "Acyclovir (ACV)-resistant herpes simplex virus type 2 (HSV-2) was isolated from a patient with acquired immunodeficiency syndrome after long-term but intermittent ACV therapy." | 3.68 | Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome. ( Birch, CJ; Doherty, RR; Gust, ID; Hayes, K; Tachedjian, G, 1990) |
| "The drug sensitivities of human immunodeficiency virus (HIV) isolates from a group of patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related complex (ARC) who were receiving zidovudine (3'-azido-3'-deoythymidine, AZT) therapy were tested by means of a newly developed plaque assay in CD4+ HeLa cells." | 3.67 | HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. ( Darby, G; Larder, BA; Richman, DD, 1989) |
| "To determine whether trisodium phosphonoformate (foscarnet) is efficacious in treating severe mucocutaneous disease due to acyclovir-resistant herpes simplex virus type-2 (HSV-2) infection in patients with the acquired immunodeficiency syndrome (AIDS)." | 3.67 | Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial. ( Drennan, DP; Erlich, KS; Follansbee, SE; Gooze, L; Jacobson, MA; Koehler, JE; Mills, J; Safrin, S, 1989) |
| "Ten patients with acquired immunodeficiency syndrome with newly diagnosed cytomegalovirus (CMV) retinitis were treated with an induction regimen of intravenous foscarnet, 60 mg/kg of body weight, administered as a 2-h infusion and repeated every 8 h for 14 days." | 3.67 | Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome. ( Jacobson, MA; Mills, J; O'Donnell, JJ, 1989) |
| " There was no difference between the 2 groups in either serious adverse events or rise of creatinine to > or = 2." | 2.69 | Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections. ( Benson, P; Cheung, TW; Jayaweera, DT; Nahass, R; Olson, C; Pearce, D; Wool, GM, 2000) |
| " Adverse events resulted in discontinuance of medication in the case of one patient." | 2.68 | Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS. ( Dieterich, DT; Faust, MJ; Johnson, J; Lew, EA; Martin-Munley, S; Nix, D; Poles, MA, 1997) |
| "Foscarnet was administered as a continuous infusion of 200 mg/kg (prior to 1988) or as an intermittent infusion of 60 mg/kg t." | 2.67 | Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet. ( Blanshard, C, 1992) |
| "Although initial recurrences of herpes simplex infection after the index lesion had healed tended to be susceptible to acyclovir, acyclovir-resistant infection eventually recurred in every healed patient, a median of 42." | 2.67 | A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group. ( Chatis, P; Crumpacker, C; Davis, R; Hafner, R; Kessler, HA; Landry, B; Mills, J; Rush, J; Safrin, S, 1991) |
| "Treatment with Foscarnet may be initially effective, but does not eliminate cytomegalovirus infection." | 2.66 | Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with Foscarnet (phosphonoformate). ( Barrison, I; Boylston, A; Forster, S; Jeffries, DJ; Pinching, AJ; Thom, S; Unwin, R; Weber, JN, 1987) |
| " Current work includes the development of increased bioavailability prodrugs (BW 256, famciclovir), which are converted to active drug once absorbed, enabling rapid high serum levels, and hence may turn out to have increased efficacy in HSV- and VZV-induced diseases, for which oral acyclovir currently is the treatment of choice." | 2.38 | Systemic antivirals in herpesvirus infections. ( Sacks, SL; Sasadeusz, JJ, 1993) |
| "How to treat cytomegalovirus infections in patients infected with the human immunodeficiency virus constitutes one of the best examples of the quandaries engendered by these advances, and the topic is reviewed in this first AIDS Commentary update." | 2.38 | Cytomegalovirus infection in patients with AIDS. ( Drew, WL, 1992) |
| " The serious toxicity associated with zidovudine has led researchers to develop safer dosage regimens." | 2.38 | Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease. ( Cersosimo, RJ; Matthews, SJ; Spivack, ML, 1991) |
| " Myelosuppression may be further exacerbated in AIDS patients by such other agents as zidovudine or trimethoprim/sulfamethoxazole, often necessitating dosage reductions or discontinuation of these agents in patients receiving ganciclovir." | 2.38 | Foscarnet sodium. ( Baltz, JK; Minor, JR, 1991) |
| "CMV disease is a major problem in AIDS, though with a different profile from that seen in other immunosuppressed patients." | 2.38 | Cytomegalovirus infection in the acquired immune deficiency syndrome. ( Pinching, AJ, 1989) |
| "The end-stage of these infections, acquired immune deficiency syndrome (AIDS), was first recognised in 1981, and the causative agent isolated in 1983." | 2.37 | Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date. ( Kaplan, JC; Sandström, EG, 1987) |
| " An important direction for future clinical research is the development of more effective and less toxic therapy, as well as orally bioavailable drugs for maintenance therapy." | 2.37 | Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment. ( Jacobson, MA; Mills, J, 1988) |
| "Cytomegalovirus retinitis is probably the result of hematogenous spread of the virus to the retina after systemic reactivation of a latent cytomegalovirus infection." | 2.37 | The diagnosis of cytomegalovirus retinitis. ( Bloom, JN; Palestine, AG, 1988) |
| "The lymphoproliferative disorders are usually treated with a combination of cytotoxic drugs, and virustatic medication is thought to be ineffective." | 1.31 | Regression of Epstein-Barr virus-associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet. ( Delecluse, HJ; Huhn, D; Ruhnke, M; Schneider, U; Stein, H, 2000) |
| "PFA may be an effective therapy for AIDS-related KS; prospective trials are indicated." | 1.30 | Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. ( Gee, L; Jacobson, MA; Lugo, D; Robles, R, 1999) |
| "A treatment with foscarnet was administered and clinical improvement was observed as early as the fourth day, with complete reepithelialization 50 days later." | 1.29 | [Chronic herpes resistant to acyclovir in a patient with AIDS]. ( About, I; Bernard, P; Capdeville, J; Massip, P, 1994) |
| "Among the 861 patients with AIDS treated in our unit from 1991 to 1993, 7 cases involving cytomegalovirus infection of the conus medullaris and/or the cauda equina were studied retrospectively." | 1.29 | [Lesions of the conus medullaris and the cauda equina caused by cytomegalovirus in HIV infection. 7 cases]. ( el Amrani, M; Girard, PM; Gozlan, J; Jacomet, C; Lebrette, MG; Monfort, L; Rozenbaum, W, 1995) |
| "A 41-year-old man with acquired immunodeficiency syndrome (AIDS) developed cytomegalovirus (CMV) retinitis." | 1.29 | [Foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome]. ( Fujino, Y; Kimura, S; Mochizuki, M; Mouri, H; Nagata, Y; Oka, S; Ono, A; Shimada, K, 1994) |
| "Foscarnet was administered intravenously at various dosages at 12-h intervals." | 1.29 | Penetration of foscarnet into cerebrospinal fluid of AIDS patients. ( Ghaleh, B; Huart, A; Raffi, F; Singlas, E; Taburet, AM, 1993) |
| "Sera obtained from AIDS patients with cytomegalovirus (CMV) retinitis before and after treatment with foscarnet, AIDS patients with human immunodeficiency virus (HIV) retinopathy, AIDS patients without retinal disease, and normal healthy controls with and without positive CMV serologies were assayed for the presence of antibodies against the 200-kDa outer, 160-kDa middle, and 68-kDa core subunits of the neurofilament triplet." | 1.29 | Antineurofilament and antiretinal antibodies in AIDS patients with cytomegalovirus retinitis. ( Cunningham-Rundles, S; Heinemann, MH; Klein, RF; Polsky, B; Rosberger, DF; Tshering, SL, 1994) |
| "Approximately one-third of all AIDS patients develop cytomegalovirus (CMV) retinitis." | 1.29 | Detecting CMV retinitis: know what to look for. Treatment is effective but not pleasant. ( , 1996) |
| "In persons with AIDS (PWAs), cytomegalovirus (CMV) infection can cause a broad spectrum of clinical manifestations." | 1.29 | Spectrum and treatment of cytomegalovirus disease in persons with AIDS. ( Spector, SA, 1996) |
| "Virus isolates from four AIDS patients and one bone marrow transplant recipient were examined for their sensitivity for the antiviral compounds used by means of plaque reduction assay." | 1.28 | [Acyclovir-resistant herpes simplex virus infections in immunocompromised patients]. ( Frissen, PH; Jansen, CL; Maris-Tegeler, WG; van der Noordaa, J; Weiland, HT; Wertheim-van Dillen, PM, 1992) |
| "Foscarnet was discontinued because of adverse events in 3 (3%) of 97 patients, with treatment being stopped in 2 patients because of renal insufficiency and in 1 patient because of an acute neurologic disorder." | 1.28 | Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens. ( Brancon, C; Caumes, E; Cochereau-Massin, I; Dahan, R; Dohin, E; Gentilini, M; Katlama, C; Robinet, M; Rogeaux, O, 1992) |
| " Pharmacokinetic parameters remained stable throughout the study." | 1.28 | Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients. ( Blanshard, C; Dohin, E; Frostegard, C; Gazzard, BG; Gazzard, D; Katlama, C; Singlas, E; Taburet, AM; Zorza, G, 1992) |
| "We treated a patient who had acquired immunodeficiency syndrome and cytomegalovirus retinitis of the left eye." | 1.28 | Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome. ( Chipont, E; Díaz-Llopis, M; España, E; Menezo, JL; Navea, A; Sanchez, S, 1992) |
| " TPFA had a mean terminal plasma half-life of 42 min, a total clearance of 4." | 1.28 | Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat. ( Bai, SA; de Vera, CC; Loo, TL; Nelson, PD; Straw, JA; Tompkins, WA, 1992) |
| "Foscarnet and zidovudine (ZDV) pharmacokinetic parameters were not altered in five patients receiving 14 days of concomitant therapy." | 1.28 | Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053). ( Aweeka, FT; Gambertoglio, JG; Jacobson, MA; Raasch, R; van der Horst, C, 1992) |
| "Neutropenia was the most frequent and serious side-effect of ganciclovir, 76% patients having neutrophil counts less than 1." | 1.28 | Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival. ( Anderson, S; Beck, EJ; Coker, R; Coleman, D; Harris, JR; Main, J; Migdal, C; Peters, BS; Pinching, AJ, 1991) |
| "Fifty AIDS patients were investigated for human cytomegalovirus (HCMV) viraemia when potentially HCMV-related clinical symptoms or syndromes were observed." | 1.28 | Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia. ( Gaballo, A; Gerna, G; Milanesi, G; Parea, M; Percivalle, E; Zavattoni, M; Zipeto, D, 1991) |
| " Therefore we began treatment with trisodium phosphonoformate (Foscavir) at a dosage of 60 mg/kg body weight per day (3 weeks), continuing with maintenance therapy at 90 mg/kg body weight per day (7 days a week)." | 1.28 | [Therapeutic alternative or 2d choice drug. Trisodium phosphonoformate in cytomegalovirus retinitis]. ( Gümbel, H; Helm, EB; Ohrloff, C; Schalnus, R, 1991) |
| " The combined effect of ddNTPs and the pyrophosphate analog phosphonoformate (PFA) on HIV reverse transcriptase was also examined, and inhibition by PFA in combination with ddTTP or AZTTP was mutually exclusive." | 1.28 | Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate. ( Cheng, YC; Starnes, MC, 1989) |
| "Foscarnet was distributed to the cerebrospinal fluid in a concentration varying from 13 to 68% of the simultaneous concentration in plasma." | 1.28 | Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection. ( Bergdahl, S; Movin, G; Ogenstad, S; Saarimäki, M; Sjövall, J, 1989) |
| "Foscarnet has been shown to be active in vitro against the human immunodeficiency virus and all human herpesviruses including cytomegalovirus (CMV)." | 1.28 | Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis. ( Aweeka, F; Gambertoglio, J; Jacobson, MA; Mills, J, 1989) |
| " Maintenance therapy with DHPG would appear to be necessary to prevent relapse, but the logistics of this are difficult, and the effective dosage of DHPG is as yet uncertain." | 1.27 | Treatment of CMV retinitis in an AIDS patient. ( Acheson, JF; Bradbeer, C; Shah, SM; Spalton, DJ; Thin, RN, 1987) |
| "Foscarnet (FC) is a new antiviral agent which has been recently proposed for the treatment of severe cytomegalovirus (CMV) infections in immunocompromised patients." | 1.27 | Acute renal failure induced by foscarnet: 4 cases. ( Baumelou, A; Cacoub, P; Deray, G; Gentilini, M; Jacobs, C; Le Hoang, P; Rousselie, R; Rozenbaum, W; Soubrie, C, 1988) |
| "Foscarnet was administered to eight AIDS patients for suspected cytomegalovirus (CMV) pneumonitis as a continuous intravenous infusion for a minimum of 8 days." | 1.27 | Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS. ( Anderson, MG; Chanas, AC; Ellis, ME; Farthing, C; Gazzard, BG, 1987) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 44 (19.91) | 18.7374 |
| 1990's | 161 (72.85) | 18.2507 |
| 2000's | 14 (6.33) | 29.6817 |
| 2010's | 2 (0.90) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| De Clercq, E | 1 |
| Chronister, CL | 1 |
| Kaiser, H | 1 |
| Pagani, JM | 1 |
| Torres, T | 1 |
| Fernandes, I | 1 |
| Sanches, M | 1 |
| Selores, M | 1 |
| Kimberlin, DW | 1 |
| Zambarakji, HJ | 1 |
| Obi, AA | 1 |
| Mitchell, SM | 1 |
| Ramos, C | 1 |
| Lajusticia, J | 1 |
| Baldanti, F | 1 |
| Lurain, N | 1 |
| Gerna, G | 4 |
| Francisci, D | 1 |
| Marroni, M | 1 |
| Morosi, S | 1 |
| Canovari, B | 1 |
| Belfiori, B | 1 |
| Stagni, G | 1 |
| Baldelli, F | 1 |
| Almony, A | 1 |
| Dhalla, MS | 1 |
| Feiner, L | 1 |
| Shah, GK | 1 |
| Fitzgerald, E | 1 |
| Goldman, HM | 1 |
| Miller, WG | 1 |
| Purcell, SM | 1 |
| Tachedjian, G | 3 |
| Hoy, J | 1 |
| McGavin, K | 1 |
| Birch, C | 1 |
| Poirier, TI | 1 |
| Giannetti, VJ | 1 |
| Arevalo, JF | 1 |
| Gonzalez, C | 1 |
| Capparelli, EV | 1 |
| Kirsch, LS | 1 |
| Garcia, RF | 1 |
| Quiceno, JI | 1 |
| Connor, JD | 1 |
| Gambertoglio, J | 3 |
| Bergeron-Lynn, G | 1 |
| Freeman, WR | 1 |
| About, I | 1 |
| Capdeville, J | 1 |
| Bernard, P | 1 |
| Massip, P | 1 |
| Lusso, P | 1 |
| Gallo, RC | 1 |
| Holland, GN | 1 |
| Levinson, RD | 1 |
| Jacobson, MA | 16 |
| Raffi, F | 3 |
| Jacomet, C | 2 |
| Lebrette, MG | 1 |
| el Amrani, M | 2 |
| Monfort, L | 1 |
| Gozlan, J | 2 |
| Girard, PM | 2 |
| Rozenbaum, W | 3 |
| Kaiser, L | 1 |
| Perrin, L | 1 |
| Hirschel, B | 1 |
| Furrer, H | 1 |
| Von Overbeck, J | 1 |
| Olmari, M | 1 |
| Yerly, S | 1 |
| Kindelan, JM | 1 |
| García-Lázaro, M | 1 |
| García-Herola, A | 1 |
| Jurado, R | 1 |
| Lor, E | 1 |
| Liu, YQ | 1 |
| Decker, CF | 1 |
| Tarver, JH | 1 |
| Murray, DF | 1 |
| Martin, GJ | 1 |
| Marlier, S | 1 |
| De Jaureguiberry, JP | 1 |
| Drouet, A | 1 |
| Muzellec, Y | 1 |
| Jaubert, D | 1 |
| Jones, JL | 1 |
| Hanson, DL | 1 |
| Chu, SY | 1 |
| Ward, JW | 1 |
| Jaffe, HW | 1 |
| Roullet, E | 1 |
| Assuerus, V | 1 |
| Ropert, A | 1 |
| Saïd, G | 1 |
| Baudrimont, M | 1 |
| Duvivier, C | 1 |
| Gonzales-Canali, G | 1 |
| Calligaro, KD | 1 |
| Stern, J | 1 |
| DeLaurentis, DA | 1 |
| Nagata, Y | 1 |
| Fujino, Y | 1 |
| Ono, A | 1 |
| Mochizuki, M | 1 |
| Mouri, H | 1 |
| Oka, S | 1 |
| Kimura, S | 1 |
| Shimada, K | 1 |
| Polsky, B | 4 |
| Causey, D | 1 |
| Davis, R | 2 |
| Tong, W | 1 |
| O'Donnell, JJ | 5 |
| Kuppermann, BD | 1 |
| Heinemann, MH | 4 |
| Feinberg, J | 3 |
| Lizak, P | 1 |
| Domingo, P | 1 |
| Puig, M | 1 |
| Iranzo, A | 1 |
| Lopez-Contreras, J | 1 |
| Ris, J | 1 |
| Balfour, HH | 3 |
| Benson, C | 1 |
| Braun, J | 1 |
| Cassens, B | 1 |
| Erice, A | 2 |
| Friedman-Kien, A | 1 |
| Klein, T | 1 |
| Safrin, S | 6 |
| Gross, AS | 1 |
| Dretler, RH | 1 |
| Ricart Olmos, C | 1 |
| López Aldeguer, J | 1 |
| Marino Blanes Juliá, F | 1 |
| Sinelni, E | 1 |
| Taburet, AM | 2 |
| Ghaleh, B | 1 |
| Huart, A | 1 |
| Singlas, E | 2 |
| Spaide, RF | 2 |
| Geier, SA | 1 |
| Sadri, I | 1 |
| Bogner, JR | 1 |
| Goebel, FD | 1 |
| Freifeld, AG | 1 |
| Seidel, EA | 1 |
| Koenig, S | 1 |
| Polis, MA | 4 |
| deSmet, MD | 1 |
| Baird, BF | 2 |
| Mellow, S | 1 |
| Falloon, J | 2 |
| Davey, RT | 2 |
| Kovacs, JA | 2 |
| Palestine, AG | 4 |
| Nussenblatt, RB | 1 |
| Masur, H | 2 |
| Sasadeusz, JJ | 1 |
| Sacks, SL | 1 |
| Brown, DL | 1 |
| Sather, S | 1 |
| Cheitlin, MD | 1 |
| Keijer, WJ | 1 |
| Burger, DM | 1 |
| Neuteboom, GH | 1 |
| Vrooland, JL | 1 |
| Meenhorst, PL | 1 |
| Koks, CH | 1 |
| Beijnen, JH | 1 |
| Brockmeyer, NH | 1 |
| Hengge, UR | 1 |
| Mertins, L | 1 |
| Malessa, R | 1 |
| Steinmetz, R | 1 |
| Gooss, M | 1 |
| Scieux, C | 1 |
| Bianchi, A | 1 |
| Chakrabarti, J | 1 |
| Rosberger, DF | 1 |
| Tshering, SL | 1 |
| Klein, RF | 1 |
| Cunningham-Rundles, S | 1 |
| Ljungman, P | 1 |
| López-Cortés, LF | 2 |
| Pachón-Díaz, J | 1 |
| Humphrey, RW | 1 |
| O'Brien, TR | 1 |
| Newcomb, FM | 1 |
| Nishihara, H | 1 |
| Wyvill, KM | 1 |
| Ramos, GA | 1 |
| Saville, MW | 1 |
| Goedert, JJ | 1 |
| Straus, SE | 1 |
| Yarchoan, R | 2 |
| Pollard, RB | 1 |
| Jabs, DA | 2 |
| Larkin, M | 1 |
| Becker, BN | 1 |
| Schulman, G | 1 |
| Conn, J | 1 |
| Colman, P | 1 |
| Brown, G | 1 |
| Street, A | 1 |
| Bate, K | 1 |
| Klein, JL | 1 |
| Sandy, C | 1 |
| Migdal, CS | 1 |
| Main, J | 2 |
| Martin, DF | 1 |
| Teich, SA | 2 |
| Katz, A | 1 |
| Toth, I | 1 |
| Grose, C | 1 |
| Moore, DA | 1 |
| Gazzard, BG | 9 |
| Nelson, MR | 3 |
| Manfredi, R | 1 |
| Mastroianni, A | 1 |
| Coronado, OV | 1 |
| Chiodo, F | 1 |
| Fletcher, CV | 1 |
| Henry, WK | 1 |
| Acosta, EP | 1 |
| Smith, SA | 1 |
| Holm, MA | 1 |
| Boivin, G | 1 |
| Shepp, DH | 1 |
| Crumpacker, CS | 2 |
| Eaton, CA | 1 |
| Martin-Munley, SS | 1 |
| Moorthy, RS | 1 |
| Weinberg, DV | 1 |
| Berger, BB | 1 |
| Minturn, JT | 1 |
| Kumar, S | 1 |
| Rao, NA | 1 |
| Fowell, SM | 1 |
| Loose, IA | 1 |
| Jampol, LM | 1 |
| Dieterich, DT | 1 |
| Poles, MA | 1 |
| Lew, EA | 1 |
| Martin-Munley, S | 2 |
| Johnson, J | 1 |
| Nix, D | 1 |
| Faust, MJ | 1 |
| Gayet, S | 1 |
| Ville, E | 1 |
| Durand, JM | 1 |
| Mars, ME | 1 |
| Morange, S | 1 |
| Kaplanski, G | 1 |
| Gallais, H | 1 |
| Soubeyrand, J | 1 |
| Lalezari, J | 1 |
| Schacker, T | 1 |
| Gathe, J | 1 |
| Lee, S | 1 |
| Cheung, T | 1 |
| Kramer, F | 1 |
| Kessler, H | 1 |
| Corey, L | 1 |
| Drew, WL | 6 |
| Boggs, J | 1 |
| McGuire, B | 1 |
| Jaffe, HS | 1 |
| Guillaume, MP | 1 |
| Karmali, R | 1 |
| Bergmann, P | 1 |
| Cogan, E | 1 |
| Cordero, E | 1 |
| Viciana, P | 1 |
| Alarcón, A | 1 |
| Pachón, J | 1 |
| Terra, L | 1 |
| Pellicanò, S | 1 |
| Calzone, R | 1 |
| Mandica, D | 1 |
| Milano, M | 1 |
| Cinque, P | 1 |
| Cleator, GM | 1 |
| Weber, T | 1 |
| Monteyne, P | 1 |
| Sindic, C | 1 |
| van Loon, AM | 1 |
| Klapper, PE | 1 |
| Meenken, C | 1 |
| van den Horn, GJ | 1 |
| de Smet, MD | 2 |
| van der Meer, JT | 1 |
| Devianne-Garrigue, I | 1 |
| Pellegrin, I | 1 |
| Denisi, R | 1 |
| Dupon, M | 1 |
| Ragnaud, JM | 1 |
| Barbeau, P | 1 |
| Breilh, D | 1 |
| Leng, B | 1 |
| Fleury, HJ | 1 |
| Pellegrin, JL | 1 |
| Papini, M | 1 |
| Bruni, PL | 1 |
| Vogel, JU | 1 |
| Scholz, M | 1 |
| Cinatl, J | 1 |
| Maurice-Estepa, L | 1 |
| Daudon, M | 1 |
| Katlama, C | 5 |
| Jouanneau, C | 1 |
| Sazdovitch, V | 1 |
| Lacour, B | 1 |
| Beaufils, H | 1 |
| Lateef, F | 1 |
| Don, PC | 1 |
| Kaufmann, M | 1 |
| White, SM | 1 |
| Weinberg, JM | 1 |
| Robles, R | 1 |
| Lugo, D | 1 |
| Gee, L | 1 |
| Alvarez-McLeod, A | 1 |
| Havlik, J | 1 |
| Drew, KE | 1 |
| Ferguson, CG | 1 |
| Gorin, BI | 1 |
| Thatcher, GR | 1 |
| Schneider, U | 1 |
| Ruhnke, M | 1 |
| Delecluse, HJ | 1 |
| Stein, H | 1 |
| Huhn, D | 1 |
| Huycke, MM | 1 |
| Naguib, MT | 1 |
| Stroemmel, MM | 1 |
| Blick, K | 1 |
| Monti, K | 1 |
| Kaufman, C | 1 |
| Cheung, TW | 1 |
| Jayaweera, DT | 1 |
| Pearce, D | 1 |
| Benson, P | 1 |
| Nahass, R | 1 |
| Olson, C | 1 |
| Wool, GM | 1 |
| Chou, S | 1 |
| Miner, RC | 1 |
| Roos, TC | 1 |
| Albrecht, H | 2 |
| Baker, R | 1 |
| Bowers, M | 1 |
| Spector, SA | 1 |
| Smart, T | 1 |
| Verm, AM | 1 |
| Scott, IU | 1 |
| Davis, JL | 1 |
| Healy, B | 1 |
| Hirsch, MS | 3 |
| Jansen, CL | 1 |
| Maris-Tegeler, WG | 1 |
| Wertheim-van Dillen, PM | 1 |
| Frissen, PH | 2 |
| Weiland, HT | 1 |
| van der Noordaa, J | 1 |
| Evans, JK | 1 |
| Scoular, A | 1 |
| Miller, RF | 1 |
| Nicoli, F | 1 |
| Dhiver, C | 1 |
| Chave, B | 1 |
| Poizot-Martin, I | 1 |
| Gastaut, JA | 1 |
| Gastaut, JL | 1 |
| Wilson, RJ | 1 |
| Skolnik, PR | 1 |
| Deray, G | 2 |
| Jacobs, C | 2 |
| Bachman, DM | 1 |
| Peters, M | 1 |
| Timm, U | 1 |
| Schürmann, D | 1 |
| Pohle, HD | 1 |
| Ruf, B | 1 |
| Dohin, E | 2 |
| Caumes, E | 1 |
| Cochereau-Massin, I | 1 |
| Brancon, C | 1 |
| Robinet, M | 2 |
| Rogeaux, O | 1 |
| Dahan, R | 1 |
| Gentilini, M | 2 |
| Blanshard, C | 3 |
| Hardy, WD | 2 |
| Manji, H | 1 |
| Malin, A | 1 |
| Connolly, S | 1 |
| Birch, CJ | 2 |
| Tyssen, DP | 1 |
| Doherty, R | 1 |
| Hayes, K | 2 |
| Mijch, A | 1 |
| Lucas, CR | 1 |
| Evans, LM | 1 |
| Grossman, ME | 1 |
| Cotte, L | 1 |
| Langlois, M | 1 |
| Trepo, C | 1 |
| Reddy, MM | 1 |
| Grieco, MH | 1 |
| McKinley, GF | 1 |
| Causey, DM | 1 |
| van der Horst, CM | 1 |
| Parenti, DM | 1 |
| Hooton, TM | 1 |
| Davis, RB | 1 |
| Levinson, ML | 1 |
| Jacobson, PA | 1 |
| Moyle, G | 1 |
| Harman, C | 1 |
| Mitchell, S | 1 |
| Mathalone, B | 1 |
| Zorza, G | 1 |
| Gazzard, D | 1 |
| Frostegard, C | 1 |
| Díaz-Llopis, M | 1 |
| Chipont, E | 1 |
| Sanchez, S | 1 |
| España, E | 1 |
| Navea, A | 1 |
| Menezo, JL | 1 |
| Morris, DJ | 1 |
| Wood, CA | 1 |
| Enting, R | 1 |
| de Gans, J | 1 |
| Reiss, P | 2 |
| Jansen, C | 1 |
| Portegies, P | 1 |
| Straw, JA | 1 |
| Loo, TL | 1 |
| de Vera, CC | 1 |
| Nelson, PD | 1 |
| Tompkins, WA | 1 |
| Bai, SA | 1 |
| Ferré, C | 1 |
| Pujol, M | 1 |
| Carratalá, J | 1 |
| Gómez, N | 1 |
| Aweeka, FT | 1 |
| Gambertoglio, JG | 2 |
| van der Horst, C | 1 |
| Raasch, R | 1 |
| el-Chaar, GM | 1 |
| Schwenk, MH | 1 |
| Bardini, J | 1 |
| Caliendo, G | 1 |
| Frank, C | 1 |
| Profeta, LM | 1 |
| Talbot, KA | 1 |
| Cohen, H | 1 |
| Cox, SW | 1 |
| Wahren, B | 1 |
| Longuet, P | 1 |
| Leport, C | 1 |
| Whitmore, PV | 1 |
| Miner, RD | 1 |
| Parenti, D | 1 |
| Berger, TG | 1 |
| Gilson, I | 1 |
| Wolfe, PR | 1 |
| Wofsy, CB | 1 |
| Mills, J | 10 |
| Biron, KK | 1 |
| Connolly, GM | 2 |
| Hawkins, DA | 3 |
| Crumpacker, C | 1 |
| Chatis, P | 1 |
| Hafner, R | 1 |
| Rush, J | 2 |
| Kessler, HA | 1 |
| Landry, B | 1 |
| MacGregor, RR | 1 |
| Graziani, AL | 1 |
| Weiss, R | 1 |
| Grunwald, JE | 1 |
| Zurlo, JJ | 1 |
| Zunich, KM | 1 |
| Davis, M | 1 |
| Marwick, C | 1 |
| Nightingale, SL | 1 |
| Minor, JR | 3 |
| Peters, BS | 2 |
| Beck, EJ | 1 |
| Anderson, S | 1 |
| Coleman, D | 1 |
| Coker, R | 1 |
| Migdal, C | 1 |
| Harris, JR | 1 |
| Pinching, AJ | 4 |
| Lowenstein, W | 1 |
| Fadlallah, JP | 1 |
| Roudière, L | 1 |
| Deneux, C | 1 |
| Haas, C | 1 |
| Durand, H | 1 |
| Harb, GE | 1 |
| Bacchetti, P | 1 |
| Zipeto, D | 1 |
| Parea, M | 1 |
| Percivalle, E | 1 |
| Zavattoni, M | 2 |
| Gaballo, A | 1 |
| Milanesi, G | 1 |
| Gümbel, H | 1 |
| Ohrloff, C | 1 |
| Schalnus, R | 1 |
| Helm, EB | 1 |
| Jenkins, RE | 1 |
| Barter, G | 1 |
| Hawkins, D | 1 |
| Chrisp, P | 1 |
| Clissold, SP | 1 |
| Söderlund, C | 1 |
| Bratt, G | 1 |
| Grützmeier, S | 1 |
| Rieger, A | 1 |
| Sandström, E | 4 |
| Sjunnesson, M | 1 |
| Matthews, SJ | 1 |
| Cersosimo, RJ | 1 |
| Spivack, ML | 1 |
| Bratzke, B | 1 |
| Orfanos, CE | 1 |
| Stavermann, T | 1 |
| Ehlers, G | 1 |
| Stellbrink, HJ | 1 |
| Löning, T | 1 |
| Greten, H | 1 |
| Bevilacqua, F | 1 |
| Marcello, A | 1 |
| Toni, M | 1 |
| Cusini, M | 1 |
| Zerboni, R | 1 |
| Palù, G | 1 |
| Baltz, JK | 2 |
| Van Der Pijl, JW | 1 |
| Hulsebosch, HJ | 1 |
| Van Den Tweel, JG | 1 |
| Lange, JM | 1 |
| Danner, SA | 1 |
| Gilquin, J | 1 |
| Weiss, L | 1 |
| Kazatchkine, MD | 1 |
| Lortholary, A | 1 |
| Aubertin, P | 1 |
| Barrier, JH | 1 |
| Boibieux, A | 1 |
| Peyramond, D | 1 |
| Kennedy, P | 1 |
| Gallelli, J | 1 |
| Green, ST | 1 |
| Nathwani, D | 1 |
| Goldberg, DJ | 1 |
| Mack, DJ | 1 |
| Kennedy, DH | 1 |
| Youle, M | 1 |
| Chanas, A | 3 |
| Gazzard, B | 2 |
| Fanning, MM | 2 |
| Read, SE | 2 |
| Benson, M | 1 |
| Vas, S | 1 |
| Rachlis, A | 2 |
| Kozousek, V | 1 |
| Mortimer, C | 1 |
| Harvey, P | 1 |
| Schwartz, C | 1 |
| Chew, E | 2 |
| Farese, RV | 1 |
| Schambelan, M | 1 |
| Hollander, H | 1 |
| Stringari, S | 1 |
| Assaykeen, T | 1 |
| Follansbee, S | 1 |
| Doherty, RR | 1 |
| Gust, ID | 1 |
| Cotton, P | 1 |
| Kaplan, JC | 2 |
| Vogt, M | 1 |
| Schooley, RT | 2 |
| Pomerantz, RJ | 1 |
| Larder, BA | 1 |
| Darby, G | 1 |
| Richman, DD | 2 |
| Montefiori, DC | 1 |
| Robinson, WE | 1 |
| Mitchell, WM | 1 |
| Starnes, MC | 1 |
| Cheng, YC | 1 |
| Erlich, KS | 1 |
| Koehler, JE | 1 |
| Follansbee, SE | 1 |
| Drennan, DP | 2 |
| Gooze, L | 1 |
| MacPhail, LA | 1 |
| Greenspan, D | 1 |
| Schiødt, M | 1 |
| Sjövall, J | 2 |
| Bergdahl, S | 2 |
| Movin, G | 1 |
| Ogenstad, S | 2 |
| Saarimäki, M | 2 |
| Chatis, PA | 1 |
| Miller, CH | 1 |
| Schrager, LE | 1 |
| Lehoang, P | 1 |
| Girard, B | 1 |
| Marcel, P | 1 |
| Zazoun, L | 1 |
| Matheron, S | 1 |
| Morer, I | 1 |
| Lernestedt, JO | 2 |
| Aweeka, F | 2 |
| Wood, G | 1 |
| Whitby, M | 1 |
| Hogan, P | 1 |
| Frazer, I | 1 |
| Sandström, EG | 1 |
| Acheson, JF | 1 |
| Shah, SM | 1 |
| Spalton, DJ | 1 |
| Bradbeer, C | 1 |
| Thin, RN | 1 |
| Walmsley, SL | 1 |
| Vellend, H | 1 |
| Salit, I | 1 |
| Cacoub, P | 1 |
| Baumelou, A | 1 |
| Le Hoang, P | 2 |
| Soubrie, C | 1 |
| Rousselie, R | 1 |
| Broder, S | 1 |
| Crowe, S | 1 |
| Levy, J | 1 |
| McManus, N | 1 |
| Miller, RG | 1 |
| Greco, C | 1 |
| Gonzales, MF | 1 |
| Bloom, JN | 1 |
| Wyngaarden, JB | 1 |
| Michon, C | 1 |
| Ngovan, P | 1 |
| Simonpoli, AM | 1 |
| Beldekas, JC | 1 |
| Levy, EM | 1 |
| Black, P | 1 |
| Von Krogh, G | 1 |
| Sönnerborg, A | 1 |
| Larsson, A | 1 |
| Strannegard, O | 1 |
| Youle, MS | 1 |
| Clarbour, J | 1 |
| Youle, MM | 1 |
| Collins, P | 1 |
| Shanson, DC | 1 |
| Evans, R | 1 |
| Oliver, N | 1 |
| Lawrence, A | 1 |
| Heley, A | 1 |
| Hunt, AF | 1 |
| Jones, MT | 1 |
| Howkins, GJ | 1 |
| Weber, J | 1 |
| Farthing, CF | 1 |
| Dalgleish, AG | 1 |
| Clark, A | 1 |
| McClure, M | 1 |
| Gaub, J | 1 |
| Pedersen, C | 1 |
| Poulsen, AG | 1 |
| Mathiesen, LR | 1 |
| Ulrich, K | 1 |
| Lindhardt, BO | 1 |
| Faber, V | 1 |
| Gerstoft, J | 1 |
| Hofmann, B | 1 |
| Karlsson, A | 1 |
| Singer, DR | 1 |
| Fallon, TJ | 1 |
| Schulenburg, WE | 1 |
| Williams, G | 1 |
| Cohen, J | 1 |
| Brochard, L | 1 |
| Salmeron, S | 1 |
| Herve, P | 1 |
| Petitpretz, P | 1 |
| Boissonnas, A | 1 |
| Simonneau, G | 1 |
| Duroux, P | 1 |
| Weber, JN | 1 |
| Thom, S | 1 |
| Barrison, I | 1 |
| Unwin, R | 1 |
| Forster, S | 1 |
| Jeffries, DJ | 1 |
| Boylston, A | 1 |
| Farthing, C | 1 |
| Anderson, MG | 1 |
| Ellis, ME | 1 |
| Chanas, AC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome[NCT00000726] | Phase 1 | 53 participants | Interventional | Completed | |||
| An Open, Multicenter Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies[NCT00002272] | 0 participants | Interventional | Completed | ||||
| An Open Study of Foscarnet Treatment of Acyclovir-Resistant Herpes Simplex Virus in Patients With the Acquired Immunodeficiency Syndrome and Other Immunodeficiencies[NCT00002021] | 0 participants | Interventional | Completed | ||||
| [NCT00005228] | 0 participants | Observational | 1988-07-31 | Completed | |||
| CMV Retinitis Retreatment Trial[NCT00000766] | Phase 2 | 300 participants | Interventional | Completed | |||
| Phase III Multicenter, Open-Label, Randomized Trial of Induction Versus Induction Plus Maintenance Foscarnet ( Foscavir ) Therapy for Gastrointestinal CMV Disease[NCT00002145] | Phase 3 | 145 participants | Interventional | Completed | |||
| Foscarnet-Ganciclovir CMV Retinitis Trial[NCT00000136] | Phase 3 | 234 participants (Actual) | Interventional | 1990-03-31 | Completed | ||
| A Phase I/II Pilot Treatment Study Of CSF Penetration And Response To Ganciclovir And Foscarnet In CMV Neurologic Disease.[NCT00000856] | Phase 1 | 0 participants (Actual) | Interventional | Withdrawn | |||
| Studies of the Ocular Complications of AIDS (SOCA) CMV Retinitis Trial: Foscarnet-Ganciclovir Component[NCT00000665] | 240 participants | Interventional | Completed | ||||
| A Phase II Dose-Ranging, Open-Labelled Trial of Foscarnet Salvage Therapy for AIDS Patients With Sight-Threatening CMV Retinitis Who Cannot Be Treated With Ganciclovir Due To Myelosuppression or Treatment Failure[NCT00000691] | Phase 2 | 156 participants | Interventional | Completed | |||
| Intermittent Foscarnet Therapy for Human Immunodeficiency Virus Infection in Patients Receiving Long-Term Zidovudine Therapy[NCT00001002] | Phase 1 | 12 participants | Interventional | Completed | |||
| A Multi-centered, Randomized Study to Evaluate the Efficacy and Safety of Foscarnet Sodium and Sodium Chloride Injection Compared to Intravenous Acyclovir in Patients With Herpes Zoster From China[NCT02151240] | Phase 4 | 94 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Treatment of Acyclovir-Resistant Mucocutaneous Herpes Simplex Infection in Patients With the Acquired Immunodeficiency Syndrome: A Randomized Multicenter Study of Foscarnet Versus Vidarabine[NCT00000985] | Phase 3 | 26 participants | Interventional | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000136)
Timeframe: All patients enrolled will be followed until a common study closing date, which was chosen to provide a minimum of 1 year of follow-up for all patients enrolled in the trial.
| Intervention | participants (Number) |
|---|---|
| Foscarnet | 107 |
| Ganciclovir | 127 |
39 reviews available for foscarnet and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Chemotherapeutic approaches to the treatment of the acquired immune deficiency syndrome (AIDS).
Topics: Acquired Immunodeficiency Syndrome; Adsorption; Antibodies, Viral; Antigens, Viral; Aurintricarboxyl | 1986 |
Clinical and biologic aspects of human cytomegalovirus resistance to antiviral drugs.
Topics: Acquired Immunodeficiency Syndrome; Antiretroviral Therapy, Highly Active; Cidofovir; Cytomegaloviru | 2004 |
Human herpesvirus 6.
Topics: Acquired Immunodeficiency Syndrome; Adult; Animals; Antibodies, Viral; Base Sequence; Child; Child, | 1995 |
[Cytomegalovirus infections in AIDS].
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cytomegalovirus Infection | 1995 |
Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Algorithms; Drug Resistance, Microbial; Female | 1994 |
Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Algorithms; Drug Resistance, Microbial; Female | 1994 |
Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Algorithms; Drug Resistance, Microbial; Female | 1994 |
Management of acyclovir-resistant herpes simplex and varicella-zoster virus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Algorithms; Drug Resistance, Microbial; Female | 1994 |
Infectious complications in the immunocompromised host. The antimicrobial armamentarium.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Aminoglycosides; Amphotericin B; Anti-Bacterial Agent | 1993 |
Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet).
Topics: Acquired Immunodeficiency Syndrome; Cohort Studies; Cytomegalovirus Infections; Didanosine; Drug Tol | 1993 |
Systemic antivirals in herpesvirus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Animals; Antiviral Agents; Clinical Trials as Topic; | 1993 |
Ocular complications of the acquired immunodeficiency syndrome. Focus on the treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Cytomegalovirus Infections; Eye Diseases; Foscarnet; Ganciclovir | 1993 |
[Resistance of herpes simplex viruses to antiviral drugs].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; AIDS-Related Opportunistic Infections; DNA-Directed D | 1993 |
Cytomegalovirus pneumonia: presentation, diagnosis, and treatment.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Bone Marrow Transplantation; Cytomegalovirus I | 1995 |
Nephrotoxicity of antiviral therapies.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1996 |
Childhood infections with human herpesviruses types 6, 7, and 8.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Antiviral Agents; Burkitt Lymphoma; Central Nervous | 1996 |
Diagnosis and clinical management of neurological disorders caused by cytomegalovirus in AIDS patients. European Union Concerted Action on Virus Meningitis and Encephalitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Diagnostic Techniq | 1998 |
Treatment of cytomegalovirus diseases.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cytosin | 1997 |
Characteristics of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Cytomegalovirus infection in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Chorioretinitis; Cytomegalovirus Infections; Encephalitis; Fosca | 1992 |
Cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Diagnosis, Differe | 1992 |
Combined and alternating ganciclovir and foscarnet in acute and maintenance therapy of human immunodeficiency virus-related cytomegalovirus encephalitis refractory to ganciclovir alone. A case report and review of the literature.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infect | 1992 |
Foscarnet therapy for AIDS-related opportunistic herpesvirus infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Resistance, Microbial; Drug Therapy, Comb | 1992 |
Foscarnet-induced penile ulcer.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
Treatment and prophylaxis of cytomegalovirus disease.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
New drugs on the horizon.
Topics: Acquired Immunodeficiency Syndrome; Aminosalicylic Acids; Antibodies, Monoclonal; Antibodies, Monocl | 1992 |
Foscarnet therapy in persons with AIDS: clinical research and management considerations. Introduction.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Administration Schedule; Foscarnet; Human | 1992 |
[Prophylactic treatments of opportunistic infections in acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Drug Therapy, Combination; Foscarnet; Ganciclovir; Humans; Male; | 1992 |
Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Anemia; Animals; Antiviral Agents; Cytomegalovirus; Cytomegalovi | 1991 |
Zidovudine and other reverse transcriptase inhibitors in the management of human immunodeficiency virus-related disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Child; Didanosine; Female; Foscarnet; H | 1991 |
Foscarnet sodium.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Prospects of therapy for infections with human T-lymphotropic virus type III.
Topics: Acquired Immunodeficiency Syndrome; Anti-Bacterial Agents; Antimony; Antiviral Agents; Combined Moda | 1985 |
Therapy of human immunodeficiency virus infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Foscarnet; Humans; Immunotherapy; Interferons; | 1987 |
Cotton-wool spots and cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Cytomegalovirus Infections; Diabetic Retinopathy; Dia | 1989 |
Cytomegalovirus infection in the acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Addison Disease; Antiviral Agents; Colitis; Cytomegal | 1989 |
Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Forecasting; Foscarnet; Immunotherap | 1987 |
Serious cytomegalovirus disease in the acquired immunodeficiency syndrome (AIDS). Clinical findings, diagnosis, and treatment.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1988 |
Progress in the development of antiviral therapy for HTLV-III-associated diseases.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; HIV; Humans; Phosphonoace | 1987 |
The diagnosis of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Diagnos | 1988 |
The treatment of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Dideoxynucleosides; | 1988 |
[Treatment of cytomegalovirus infections in immunosuppressed patients].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1988 |
Antiviral drugs for AIDS. Current status and future prospects.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; Humans; Interferon Type I | 1986 |
32 trials available for foscarnet and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Dose-related difference in progression rates of cytomegalovirus retinopathy during foscarnet maintenance therapy. AIDS Clinical Trials Group Protocol 915 Team.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Re | 1995 |
Foscarnet decreases human immunodeficiency virus RNA.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; CD4 Lymphocyte Count; Cyt | 1995 |
Pharmacodynamic relationship of pharmacokinetic parameters of maintenance doses of foscarnet and clinical outcome of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Aged; Chromatography, High Pressure Liquid; C | 1994 |
A dose escalation study to determine the toxicity and maximally tolerated dose of foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Creatinine; Dose-Response Relationship, Drug; Foscarnet; | 1993 |
Increased survival of a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis who received sodium phosphonoformate (foscarnet).
Topics: Acquired Immunodeficiency Syndrome; Cohort Studies; Cytomegalovirus Infections; Didanosine; Drug Tol | 1993 |
CMV retinitis: ganciclovir/monoclonal antibody.
Topics: Acquired Immunodeficiency Syndrome; Antibodies, Monoclonal; Antiviral Agents; Cytomegalovirus Retini | 1996 |
Design of clinical trials for drug combinations: cytomegalovirus retinitis--foscarnet and ganciclovir. The CMV retinitis retreatment trial.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Retinitis; Disease Progression | 1996 |
Effect of foscarnet on quantities of cytomegalovirus and human immunodeficiency virus in blood of persons with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1996 |
Treatment of gastrointestinal cytomegalovirus infection with twice-daily foscarnet: a pilot study of safety, efficacy, and pharmacokinetics in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Animals; Antiviral | 1997 |
Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Adolescent; Adult; Antiviral Agents; Cytomegalovirus Infections; | 1997 |
A randomized, double-blind, placebo-controlled trial of cidofovir gel for the treatment of acyclovir-unresponsive mucocutaneous herpes simplex virus infection in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Animals; Antiviral Agents; Cells, Cultured; Ch | 1997 |
A double-blind placebo-controlled crossover trial of intravenous magnesium sulfate for foscarnet-induced ionized hypocalcemia and hypomagnesemia in patients with AIDS and cytomegalovirus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Calcium; Cross-Ove | 2000 |
Safety of oral versus intravenous hydration during induction therapy with intravenous foscarnet in AIDS patients with cytomegalovirus infections.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adult; AIDS-Related Opportunistic Infectio | 2000 |
The treatment of cytomegalovirus in AIDS--more than meets the eye.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Comb | 1992 |
Design of a randomized controlled trial of foscarnet in patients with cytomegalovirus retinitis associated with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG).
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1992 |
Treatment of HIV-related cytomegalovirus disease of the gastrointestinal tract with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Female; Foscarnet; | 1992 |
Effect of foscarnet therapy on human immunodeficiency virus p24 antigen levels in AIDS patients with cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Dose-Response Relationship, D | 1992 |
Foscarnet and Ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Mortality in patients with the acquired immunodeficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; CD4-Positive T-Lymphocytes; Cytomegalov | 1992 |
Foscarnet treatment of acyclovir-resistant herpes simplex virus infection in patients with acquired immunodeficiency syndrome: preliminary results of a controlled, randomized, regimen-comparative trial.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Foscarn | 1992 |
A controlled trial comparing foscarnet with vidarabine for acyclovir-resistant mucocutaneous herpes simplex in the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; | 1991 |
AIDS file.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1991 |
A randomized, controlled trial of foscarnet in the treatment of cytomegalovirus retinitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1991 |
Foscarnet versus ganciclovir in the management of cytomegalovirus disease in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1991 |
Treatment of acquired immune deficiency syndrome (AIDS)-related pneumonitis with foscarnet: a double-blind placebo controlled study.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; D | 1990 |
[Chemotherapy and immunoprophylaxis of HIV infection].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Foscarnet; HIV; Huma | 1986 |
From the National Institutes of Health. Progress in AIDS research.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1988 |
The treatment of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Dideoxynucleosides; | 1988 |
Phosphonoformate (foscarnet): a pilot study in AIDS and AIDS related complex.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Antigens, Viral; Clinical Trials as Topic; | 1987 |
The effect of foscarnet (phosphonoformate) on human immunodeficiency virus isolation, T-cell subsets and lymphocyte function in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antibodies, Viral; Clinical Trials as Topic; Foscarnet; H | 1987 |
Cytomegalovirus colitis and oesophageal ulceration in the context of AIDS: clinical manifestations and preliminary report of treatment with Foscarnet (phosphonoformate).
Topics: Acquired Immunodeficiency Syndrome; Adult; Clinical Trials as Topic; Colitis; Cytomegalovirus Infect | 1987 |
152 other studies available for foscarnet and Acquired Immune Deficiency Syndrome
| Article | Year |
|---|---|
Progressive outer retinal necrosis in a patient with acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Diagnosis, Differential; Disease Progression; | 2011 |
Foscarnet-induced penile ulceration.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Foscarnet; Humans; Male; Penile Disease | 2011 |
Antiviral therapy for cytomegalovirus infections in pediatric patients.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Adolescent; Adult; AIDS-Related Opportunis | 2002 |
Successful treatment of varicella zoster virus retinitis with aggressive intravitreal and systemic antiviral therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cidofovir; Cytosine; Drug Therapy, Comb | 2002 |
[Infection due to acyclovir-resistant varicella-zoster herpes virus in a patient with AIDS].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Cidofovir; Cytosine; Drug Re | 2004 |
Fatal haemolytic uraemic syndrome in an AIDS patient with disseminated adenovirus and cytomegalovirus co-infection.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adenovirus Infections, Human; Colitis; Cyto | 2006 |
Macular optical coherence tomography findings in progressive outer retinal necrosis.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Aqueous Humor; DNA, Viral; Drug The | 2007 |
A penile ulceration in a patient with the acquired immunodeficiency syndrome. Foscarnet-induced penile ulceration.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; H | 1995 |
Long-term foscarnet therapy not associated with the development of foscarnet-resistant human immunodeficiency virus type 1 in an acquired immunodeficiency syndrome patient.
Topics: Acquired Immunodeficiency Syndrome; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Fo | 1994 |
Clinical and ethical perspectives on rationing of high-cost drugs.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antibodies, Monoclonal; Beneficence; Decision Making; Dru | 1995 |
Intravitreous and plasma concentrations of ganciclovir and foscarnet after intravenous therapy in patients with AIDS and cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Retinitis; Drug Therapy, Combination; Fem | 1995 |
Drugs for AIDS and associated infections.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Amphotericin B; Antifunga | 1995 |
[Chronic herpes resistant to acyclovir in a patient with AIDS].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Buttocks; Chronic Disease; Drug Resistance; Fo | 1994 |
[Lesions of the conus medullaris and the cauda equina caused by cytomegalovirus in HIV infection. 7 cases].
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Cauda Equina; Cyto | 1995 |
[Hypocalcemia in a patient with the acquired immunodeficiency syndrome treated only with foscarnet].
Topics: Acquired Immunodeficiency Syndrome; Adult; Fatal Outcome; Foscarnet; HIV-1; Humans; Hypocalcemia; Ma | 1994 |
Neurologic sequelae associated with foscarnet therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Foscarnet; Hand; Humans; Infusions, Intravenous; Male; Mu | 1994 |
Prolonged concurrent use of ganciclovir and foscarnet in the treatment of polyradiculopathy due to cytomegalovirus in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Drug Administration Schedule; | 1994 |
[Early reappearance of varicella-zona virus in the cerebrospinal fluid after treatment with foscarnet in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Female; Foscarnet; Herpesvirus 3, Human; Humans; Middle Aged; Ti | 1994 |
AIDS-associated Kaposi's sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; AIDS-Related Opportunistic Infections; Female; Foscar | 1995 |
Cytomegalovirus multifocal neuropathy in AIDS: analysis of 15 consecutive cases.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus; Cytomegalovirus Infections; DNA, Viral; | 1994 |
Foscarnet: a possible cause of ulnar artery thrombosis in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Arterial Occlusive Diseases; Foscarnet; Humans; Male; Per | 1994 |
[Foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus Re | 1994 |
Polyradiculopathy due to cytomegalovirus infection: report of a case in which an AIDS patient responded to foscarnet therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Cytomegalovirus; C | 1994 |
Foscarnet-induced penile ulcer in an uncircumcised patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Foscarnet; Humans; Male; Penile Diseases; Skin Ulcer | 1993 |
[Herpes zoster during foscarnet treatment in an AIDS patient].
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis | 1993 |
Penetration of foscarnet into cerebrospinal fluid of AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Female; Foscarnet; Humans; Hydrogen-Ion Concentration; In | 1993 |
Ganciclovir intraocular device and patient survival.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis | 1994 |
Ganciclovir intraocular device and patient survival.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Opportunistic Infections; Cytomegalovirus Retinitis | 1994 |
Reversible cardiac dysfunction associated with foscarnet therapy for cytomegalovirus esophagitis in an AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Acute Disease; Adult; AIDS-Related Opportunistic Infections; Cyt | 1993 |
Foscarnet treatment in various cytomegalovirus infections.
Topics: Acquired Immunodeficiency Syndrome; Colitis; Cytomegalovirus Infections; Eye Infections, Viral; Fiss | 1993 |
Endocrine effects of HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Foscarnet; Humans; Hypocalcemia; Magnesium; Pentamidine | 1993 |
Antineurofilament and antiretinal antibodies in AIDS patients with cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antibodies; Antiviral Agents; Cytomegalovirus Retinitis; Foscarn | 1994 |
[Current status of the management of cytomegalovirus retinitis in patients with AIDS].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Retinitis; Foscarnet; Ganciclo | 1996 |
Kaposi's sarcoma (KS)-associated herpesvirus-like DNA sequences in peripheral blood mononuclear cells: association with KS and persistence in patients receiving anti-herpesvirus drugs.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Base Sequence; Blood Coagulation Disord | 1996 |
Some antivirals may lower Kaposi's sarcoma risk.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Foscarnet; Ganciclovir; Humans; Sarcoma, Kapos | 1996 |
Isolation of new transmissible herpesvirus suggests additional therapeutic approaches for KS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; DNA, Viral; Foscarnet; Herpesviridae; Herpesvi | 1996 |
Nephrogenic diabetes insipidus associated with foscarnet--a case report.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1996 |
Famciclovir in AIDS-related acute retinal necrosis.
Topics: 2-Aminopurine; Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Famciclovir; Foscarnet; | 1996 |
Successful treatment of progressive outer retinal necrosis syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Female; Foscarnet; Fundus Oc | 1996 |
Central venous line infections in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1997 |
The treatment of AIDS-related cytomegalovirus disease with ganciclovir and foscarnet association. Three case reports.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Therap | 1996 |
Management of varicella zoster virus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; AIDS-Related Opportunistic Infections; Analysi | 1997 |
Foscarnet-induced hypercalcaemia in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1997 |
Unusual prolonged hypocalcemia due to foscarnet in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Foscarnet; Humans; Hypocalcemia; Magnesium; Ma | 1997 |
Foscarnet and AIDS-associated Kaposi's sarcoma.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Foscarnet; Humans; Male; Sarcoma, Kapos | 1997 |
[Cytomegalovirus pneumonia in patients with AIDS treated foscarnet. Our experience].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Female; Fos | 1997 |
Optic neuritis heralding varicella zoster virus retinitis in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; AIDS-Related Opportunistic Infections; Antivir | 1998 |
Foscarnet decreases HIV-1 plasma load.
Topics: Acquired Immunodeficiency Syndrome; Adult; Aged; Antiviral Agents; Cytomegalovirus Infections; Femal | 1998 |
[A case for diagnosis: penile ulcer induced by foscarnet].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Foscarnet; Humans; In Vitro Techniques; | 1996 |
Identification of crystals in kidneys of AIDS patients treated with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; | 1998 |
Treatment of acyclovir-resistant, foscarnet-unresponsive HSV infection with topical cidofovir in a child with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Anti-HIV Agents; Child, Preschool; Cidofovir; Cytosin | 1998 |
Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1999 |
Foscarnet treatment of genital infection due to acyclovir-resistant herpes simplex virus type 2 in a pregnant patient with AIDS: case report.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance; Female; Fos | 1999 |
Design of novel derivatives of phosphonoformate (Foscarnet) as prodrugs and antiviral agents.
Topics: Acquired Immunodeficiency Syndrome; Anti-HIV Agents; Cytomegalovirus Infections; Drug Design; Foscar | 2000 |
Regression of Epstein-Barr virus-associated lymphoproliferative disorders in patients with acquired immunodeficiency syndrome during therapy with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Epstein-Barr Virus Infections; Foscarne | 2000 |
Ganciclovir resistance: a matter of time and titre.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infections; C | 2000 |
A deletion mutation in region V of the cytomegalovirus DNA polymerase sequence confers multidrug resistance.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cidofovir; Cytomegalovirus; Cytomegalovirus Re | 2000 |
Foscarnet-associated eosinophilic folliculitis in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Eosinophils; Folliculitis; Foscarnet; Humans; Male; Rever | 2001 |
Medicare may not reimburse for certain AIDS and cancer drugs.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Cytomegalovirus Retinitis; Foscarnet; Ganciclovir; Hu | 1995 |
Advances in treatment for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antiviral Agents; Cytomegalovirus Retiniti | 1995 |
Combination therapy improves CMV treatment.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Retinitis; Drug Therapy, Combi | 1996 |
Detecting CMV retinitis: know what to look for. Treatment is effective but not pleasant.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Antiviral Agents; Cytomegalovirus Retiniti | 1996 |
Intraocular therapy for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Retinitis; Dr | 1996 |
Spectrum and treatment of cytomegalovirus disease in persons with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Central Nervous System Diseases; Cy | 1996 |
Responding to CMV neurologic infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Central Nervous System Diseases; Cytomegalovir | 1996 |
Necrotizing herpetic retinopathy associated with Ramsay Hunt syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Drug Therapy, Combination; Female; Fosc | 2002 |
From the National Institutes of Health.
Topics: Acquired Immunodeficiency Syndrome; Anti-Inflammatory Agents, Non-Steroidal; Antiviral Agents; Arthr | 1992 |
Foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Didanosine and foscarnet marketed for use by patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Didanosine; Foscar | 1992 |
Clinical implications of herpesvirus infections in patients with AIDS. Introduction.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Treatment of cytomegalovirus retinitis--1992.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
[Acyclovir-resistant herpes simplex virus infections in immunocompromised patients].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Bone Transplantation; Drug R | 1992 |
Cytomegalovirus and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
[Regressive diffuse leukoencephalitis under foscarnet in an AIDS infected patient].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Encephalitis; Fosc | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Drug Therapy, Comb | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Foscarnet induction therapy for cytomegalovirus retinitis in AIDS: comparison of twice-daily and three-times-daily regimens.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Admini | 1992 |
Therapeutic algorithm for treatment of cytomegalovirus retinitis in persons with AIDS. A roundtable summary.
Topics: Acquired Immunodeficiency Syndrome; Adult; Algorithms; Cytomegalovirus Infections; Foscarnet; Gancic | 1992 |
CMV polyradiculopathy in AIDS--suggestions for new strategies in treatment.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Foscarnet; Humans; Male; Nerv | 1992 |
Clinical effects and in vitro studies of trifluorothymidine combined with interferon-alpha for treatment of drug-resistant and -sensitive herpes simplex virus infections.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Combined Modality Therapy; C | 1992 |
Herpes simplex virus infection during foscarnet therapy.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1992 |
Pharmacokinetics of foscarnet after twice-daily administrations for treatment of cytomegalovirus disease in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Chromatography, High Pressure Liquid; C | 1992 |
Intravitreal foscarnet for cytomegalovirus retinitis in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Eye Infections, Viral; Follow | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1992 |
Foscarnet for CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Gancicl | 1992 |
Ganciclovir/foscarnet for cytomegalovirus meningoencephalitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Therap | 1992 |
Pharmacokinetics of potential anti-AIDS agents thiofoscarnet and foscarnet in the cat.
Topics: Acquired Immunodeficiency Syndrome; Administration, Oral; Animals; Antiviral Agents; Biological Avai | 1992 |
[Tetany in a patient with the acquired immunodeficiency syndrome treated with foscarnet].
Topics: Acquired Immunodeficiency Syndrome; Adult; Female; Foscarnet; Humans; Tetany | 1992 |
Pharmacokinetics of concomitantly administered foscarnet and zidovudine for treatment of human immunodeficiency virus infection (AIDS Clinical Trials Group protocol 053).
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Chromatography, High Pressure Liquid; D | 1992 |
Treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Drug Synergism; Drug Therapy, Combination; Fos | 1992 |
Foscarnet therapy for ganciclovir-resistant cytomegalovirus retinitis in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus; Cytomegalovirus Infect | 1991 |
Foscarnet therapy in five patients with AIDS and acyclovir-resistant varicella-zoster virus infection.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Cohort Studies; Drug Resista | 1991 |
Foscarnet in the treatment of cytomegalovirus infection of the esophagus and colon in patients with the acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Colitis; Cytomegalovirus Infections; Es | 1991 |
Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adult; Antiviral Agents; Cytomegalovirus In | 1991 |
National Eye Institute issues clinical alert about CMV retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Foscarnet approved for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; | 1991 |
From the Food and Drug Administration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Eye Infections, Vi | 1991 |
Cytomegalovirus infection in AIDS. Patterns of disease, response to therapy and trends in survival.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Colitis; Cytomegalovirus Infections; Female; F | 1991 |
[Prevention of genital erosions during treatments with foscarnet of cytomegalovirus infections in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1991 |
Survival of patients with AIDS and cytomegalovirus disease treated with ganciclovir or foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Female; Fos | 1991 |
Early virus isolation, early structural antigen detection and DNA amplification by the polymerase chain reaction in polymorphonuclear leukocytes from AIDS patients with human cytomegalovirus viraemia.
Topics: Acquired Immunodeficiency Syndrome; Antigens, Viral; Antiviral Agents; Cytomegalovirus; Cytomegalovi | 1991 |
[Therapeutic alternative or 2d choice drug. Trisodium phosphonoformate in cytomegalovirus retinitis].
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Chorioretinitis; Cytomegalovirus Infections; D | 1991 |
Thromboembolic disease in AIDS is associated with cytomegalovirus disease.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1991 |
Simultaneous treatment of cytomegalovirus retinitis with ganciclovir and foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Eye Infecti | 1991 |
Seeing the way forward for treatment of CMV retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Clinical Trials as Topic; Cytomegalovirus Infe | 1991 |
[Cytomegalovirus ileocolitis in patients with HIV infection is a treatable cause of severe abdominal problems].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cecum; Crohn Disease; Cytomegalovirus I | 1991 |
[Chronic erosive, therapy-resistant perianal herpes (type II) with herpes proctitis in AIDS].
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Dose-Response Relationship, | 1991 |
Herpes simplex virus type-2 ulcers resistant to acyclovir in an AIDS patient--successful treatment with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Anus Diseases; Drug Resistan | 1991 |
Acyclovir resistance/susceptibility in herpes simplex virus type 2 sequential isolates from an AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Drug Resistance, Microbial; Follow-Up Studies; | 1991 |
Foscarnet and extended survival in AIDS patients.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Foscarnet; Phosphonoacetic Acid; Survival Rate | 1991 |
Generalised cutaneous rash associated with foscarnet usage in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Erythema; Foscarnet; Humans; Male; Phos | 1991 |
Foscarnet effective in acyclovir-resistant herpes.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Drug Resistance, Microbial; Foscarn | 1991 |
Foscarnet and penile ulceration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Herpes | 1990 |
Genital and oral erosions induced by foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Foscarnet; Genital Diseases, Male; Huma | 1990 |
Penile ulcerations with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1990 |
HIV-associated haemophagocytic syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-Bacterial Agents; Antiviral Agents; Drug Therapy, Co | 1990 |
Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Chromatography, Thin Layer; Drug Combinations; | 1990 |
Generalised cutaneous rash associated with foscarnet usage in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Drug Eruptions; Foscarnet; Ganciclovir; | 1990 |
Foscarnet therapy of cytomegalovirus retinitis in AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; | 1990 |
Nephrogenic diabetes insipidus associated with foscarnet treatment of cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Diabetes In | 1990 |
Fixed drug eruption due to foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Erupti | 1990 |
Foscarnet therapy for acyclovir-resistant mucocutaneous herpes simplex virus infection in 26 AIDS patients: preliminary data.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Drug Resistance, Microbial; Female; Foscarnet; | 1990 |
Altered sensitivity to antiviral drugs of herpes simplex virus isolates from a patient with the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Aphidicolin; Deoxyguanosine; | 1990 |
Wider access provided to AIDS drugs with actions against HIV, CMV infections.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; HIV Inf | 1990 |
HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.
Topics: Acquired Immunodeficiency Syndrome; AIDS-Related Complex; Dideoxynucleosides; Drug Resistance; Fosca | 1989 |
In vitro evaluation of mismatched double-stranded RNA (ampligen) for combination therapy in the treatment of acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Alkaloids; Amphotericin B; Antiviral Agents; Drug Therapy, Combi | 1989 |
Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate.
Topics: Acquired Immunodeficiency Syndrome; Dideoxynucleosides; Dinucleoside Phosphates; DNA Replication; DN | 1989 |
Foscarnet therapy for severe acyclovir-resistant herpes simplex virus type-2 infections in patients with the acquired immunodeficiency syndrome (AIDS). An uncontrolled trial.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; | 1989 |
Acyclovir-resistant, foscarnet-sensitive oral herpes simplex type 2 lesion in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Candidiasis, Oral; Drug Resi | 1989 |
Pharmacokinetics of foscarnet and distribution to cerebrospinal fluid after intravenous infusion in patients with human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Creatine; Foscarnet; Humans; Infusions, | 1989 |
Successful treatment with foscarnet of an acyclovir-resistant mucocutaneous infection with herpes simplex virus in a patient with acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Drug Resistance, Microbial; | 1989 |
Foscarnet in the treatment of cytomegalovirus retinitis in acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Creatine; Cytomegalovirus Infections; Drug Therapy, Combi | 1989 |
Foscarnet treatment of cytomegalovirus retinitis in patients with the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Calcium; Cytomegalovirus Infections; Fo | 1989 |
Pharmacokinetics of intermittently administered intravenous foscarnet in the treatment of acquired immunodeficiency syndrome patients with serious cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1989 |
Foscarnet infusion at home.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Drug Admini | 1989 |
Treatment of CMV retinitis in an AIDS patient.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Antiviral Agents; Cytomegalovirus Infections; Foscarn | 1987 |
Treatment of cytomegalovirus retinitis with trisodium phosphonoformate hexahydrate (Foscarnet).
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1988 |
Acute renal failure induced by foscarnet: 4 cases.
Topics: Acquired Immunodeficiency Syndrome; Acute Kidney Injury; Adult; Antiviral Agents; Chorioretinitis; C | 1988 |
Effect of Foscarnet therapy on infection with human immunodeficiency virus in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; HIV; HI | 1988 |
Failure of antiviral therapy for acquired immunodeficiency syndrome-related cytomegalovirus myelitis.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Antiviral Agents; Cytomegalovirus Infections; | 1988 |
In vitro effect of foscarnet on expansion of T-cells from people with LAS and AIDS.
Topics: Acquired Immunodeficiency Syndrome; Colony-Forming Units Assay; Deltaretrovirus; Foscarnet; Humans; | 1985 |
Declining levels of HIV P24 antigen in serum during treatment with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Antigens, Viral; Antiviral Agents; Foscarnet; HIV; HIV Antigens; | 1988 |
Severe hypocalcaemia in AIDS patients treated with foscarnet and pentamidine.
Topics: Acquired Immunodeficiency Syndrome; Amidines; Foscarnet; Humans; Hypocalcemia; Organophosphorus Comp | 1988 |
Acyclovir-resistant herpes in AIDS treated with foscarnet.
Topics: Acquired Immunodeficiency Syndrome; Acyclovir; Adult; Drug Resistance, Microbial; Female; Foscarnet; | 1988 |
Foscarnet infusion at home.
Topics: Acquired Immunodeficiency Syndrome; Adult; Cytomegalovirus Infections; Foscarnet; HIV Antigens; Home | 1988 |
Effect of sodium phosphonoformate on blood group antibody detection.
Topics: Acquired Immunodeficiency Syndrome; Antibodies; Blood Grouping and Crossmatching; Coombs Test; Fosca | 1986 |
AIDS: the virus, antivirals and vaccines.
Topics: Acquired Immunodeficiency Syndrome; Antimony; Antiviral Agents; Foscarnet; Genes, Viral; HIV; Humans | 1987 |
Pharmacokinetics and absorption of foscarnet after intravenous and oral administration to patients with human immunodeficiency virus.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Bone and Bones; Calcium; Foscarnet; Glo | 1988 |
Foscarnet for cytomegalovirus retinitis.
Topics: Acquired Immunodeficiency Syndrome; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; Humans; | 1985 |
[Importance of Foscarnet in the treatment of cytomegalovirus pneumopathy in a patient with acquired immunodeficiency syndrome].
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1986 |
Treatment of cytomegalovirus pneumonitis with foscarnet (trisodium phosphonoformate) in patients with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antiviral Agents; Cytomegalovirus Infections; Foscarnet; | 1987 |